Proceedings of the 14th annual conference of INEBRIA

Abstract

Five practices that collected 6-month follow-up data (so far) had a mean screening prevalence of 25% (6-45%) of patients, with a mean practice prevalence of positive screens 16% (0-42%), and AUD diagnoses 0.7% (0%-2%). P4 Nalmefene prescribing in UK primary care: an overview of general patterns, insights from p... Clare Sharp1*, Niamh Fitzgerald1, Linda Bauld2 1Institute of Social Marketing and Health, University of Stirling, Stirling, UK; 2Usher Insti... Correspondence: Clare Sharp (clare.sharp1@stir.ac.uk) I Addiction Science & Clinical Practice i 2023, B 18(Suppl 1) b : P4 B Introduction: b Nalmefene, first approved for use in the UK NHS in 2013, is the first pharmacotherapy to be licensed for the reduction of alcohol consumption in patients with alcohol dependence. B Methods: b A mixed-methods study including a quantitative analysis of GP prescribing data (using monthly nalmefene prescribing for GP practices in England obtained from OpenPrescribing.net and patient-level data from the Clinical Practice Research Datalink (CPRD) for patients who have received nalmefene) and semi-structured interviews (n = 19) with alcohol treatment and policy professionals. The study population was 147 patients seen between March 2019 to March 2022, the pilot study sample consisted of 22 randomly selected patients. [Extracted from the article]